HTGF | High-Tech Gruenderfonds
High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Health Diagnostics
Hema.to
Seed Round in 2025
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Mediaire
Venture Round in 2024
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Aignostics
Series B in 2024
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
ABH Optics
Pre Seed Round in 2024
ABH Optics specializes in manufacturing high-quality, ultra-thin and lightweight eyeglass lenses. Their innovative lenses, designed for high myopia patients, offer enhanced comfort and aesthetic appeal without compromising vision correction. This is achieved through a proprietary material that enables significant reduction in lens thickness and weight compared to traditional lenses.
RAYDIAX
Seed Round in 2023
RAYDIAX is a manufacturer of advanced therapy-assist computed tomography (CT) systems aimed at enhancing the quality of minimally invasive medical interventions, particularly for tumor treatments. The company develops imaging solutions that integrate a navigation system with both 2D and 3D X-ray live imaging, enabling healthcare providers to perform procedures with greater safety and efficiency. RAYDIAX's technology is designed to reduce the risk of postoperative complications, ultimately resulting in shorter hospital stays and quicker recovery times for patients. Through its innovative approach, RAYDIAX seeks to improve outcomes for both patients and clinicians in the realm of cancer therapy.
InContAlert
Pre Seed Round in 2023
InContAlert is a deep tech company innovating in the field of incontinence management. It develops an mHealth device that monitors urinary bladder filling levels using advanced algorithms. The device sends alerts to users and caregivers when predefined thresholds are reached, minimizing risks associated with uncontrolled urine loss or bladder distension.
DNTOX
Seed Round in 2023
DNTOX operates a bioanalytical testing laboratory specializing in animal-free screening of chemicals. Its in vitro testing battery uses human cell models for high-content, medium-throughput chemical screening, supported by proprietary AI software. The company assists clients in identifying safe lead structures during substance development and assessing safety during approval processes.
Hema.to
Seed Round in 2023
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Nia Health
Seed Round in 2023
Nia Health develops digital health applications focused on dermatological conditions like eczema and psoriasis. Its AI-powered app provides personalized support and relief, aiming to improve patient outcomes through innovative digital solutions.
DearEmployee
Seed Round in 2023
DearEmployee GmbH is a Berlin-based company that specializes in a software-as-a-service application focused on workplace mental health. Founded in 2017, it provides a platform designed to help employers assess and manage mental stress in their organizations. The platform allows companies to scientifically measure psychological stress levels among employees and implement tailored health and HR initiatives. By addressing mental health concerns, DearEmployee aims to foster healthier and more motivating working conditions, ultimately enhancing employee productivity. Additionally, the solution complies with legal requirements for mental health risk assessments in Germany, positioning it as a vital resource for organizations committed to employee well-being.
Mbiomics
Series A in 2023
Mbiomics is a biotechnology company focused on transforming microbiome research, diagnostics, and therapeutics. The firm operates a high-throughput, low-cost platform designed for dynamic and real-time analysis and quantification of the human gut microbiome. This technology enables precise diagnostics and targeted therapies, aiming to enhance patients' lives through innovative approaches to health management.
hbox
Seed Round in 2023
HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.
Refined Laser Systems
Seed Round in 2023
Refined Laser Systems is a specialized manufacturer of biophotonics devices, focusing on stain-free tissue diagnostics using its proprietary fiber-based tunable picosecond laser technology. The company's innovative laser systems enable rapid and reliable diagnoses, significantly reducing the time required compared to traditional methods.
neotiv
Seed Round in 2022
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.
Aignostics
Series A in 2022
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
C-mo Medical Solutions
Seed Round in 2022
C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.
Noscendo
Venture Round in 2022
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.
Ebenbuild
Seed Round in 2022
Ebenbuild is a technology company that specializes in developing and commercializing advanced health tech solutions focused on respiratory diseases. Building on two decades of research from TU Munich, the company employs lung simulation models to create a versatile platform with applications in both drug development and healthcare. One of its key innovations is a digital trials application that enhances drug delivery predictions, thereby accelerating the drug development process for Biotech, Pharma, and MedTech companies. This application allows for the optimization of delivery parameters before clinical trials, thus increasing success rates. Additionally, Ebenbuild's healthcare application integrates with hospital IT systems to provide actionable intelligence at the patient's bedside. It focuses on personalizing mechanical ventilation for patients with Acute Respiratory Distress Syndrome, significantly improving their prognosis. By continuously expanding its platform to address various indications, Ebenbuild aims to enhance patient outcomes while supporting medical staff and healthcare systems.
Newsenselab (M-sense)
Seed Round in 2021
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
PreComb
Seed Round in 2021
PreComb develops advanced technologies to adapt cancer therapies to individual patients, aiming to enhance treatment success rates and improve patient outcomes.
Mediaire
Seed Round in 2020
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
heartbeat medical
Series A in 2020
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Aignostics
Seed Round in 2020
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
Loewi
Seed Round in 2020
Loewi GmbH, founded in 2019 and based in Munich, Germany, operates an online platform specializing in non-pharmacy medical products, including medical self-tests and health products. As a scientific spin-off from the Technical University of Munich, the company aims to make personalized health and nutrition accessible to a wider audience. Loewi emphasizes a healthy and active lifestyle, focusing on data-driven personalization derived from evidence-based methods utilized in competitive sports over the past twelve years. The company offers personalized diet recommendations and supplements tailored to individual test results and health needs, promoting the analysis of nutrient requirements to help customers achieve their full potential. Loewi's commitment to integrating science and technology into its offerings is complemented by collaborations with leading universities and research institutions, reinforcing its role in advancing the industry.
Noscendo
Series A in 2020
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.
iATROS
Seed Round in 2020
iATROS GmbH is a Munich-based company founded in 2019 that specializes in developing a mobile application and platform aimed at enhancing the care of cardiology patients. The platform connects patients with medical caregivers and offers a range of services, including therapy and medication planning, progress tracking, ECG diagnosis, and the maintenance of blood pressure and sugar databases. It also facilitates consultations with physicians and enables the secure storage of health data. As the prevalence of cardiovascular diseases increases, iATROS aims to improve the lives of both chronic and acute patients while addressing the significant healthcare costs associated with these conditions. By leveraging smart health trackers, vital data collection, and advanced AI analytics, the company enhances treatment outcomes and provides patients with 24/7 access to healthcare professionals, ensuring they feel safe in managing their conditions.
DearEmployee
Venture Round in 2019
DearEmployee GmbH is a Berlin-based company that specializes in a software-as-a-service application focused on workplace mental health. Founded in 2017, it provides a platform designed to help employers assess and manage mental stress in their organizations. The platform allows companies to scientifically measure psychological stress levels among employees and implement tailored health and HR initiatives. By addressing mental health concerns, DearEmployee aims to foster healthier and more motivating working conditions, ultimately enhancing employee productivity. Additionally, the solution complies with legal requirements for mental health risk assessments in Germany, positioning it as a vital resource for organizations committed to employee well-being.
Newsenselab (M-sense)
Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Zahnarzt-Helden
Seed Round in 2019
Zahnarzt-Helden GmbH is a Bielefeld-based company that operates an online platform designed to assist dentists in identifying and acquiring essential dental equipment and services. Established in 2017, the company offers a diverse range of products, including Orthopantomograms, deep vein thrombosis scanners, Cephalometric devices, intraoral X-rays, intraoral scanners, autoclaves, thermodisinfectors, CAD/CAM systems, and management software. In addition to providing access to these products, Zahnarzt-Helden offers consultation services to help practitioners select the appropriate equipment, negotiate with manufacturers and dealers, and ensure reliable construction, maintenance, and long-term technical support. The platform aims to provide a transparent and user-friendly experience, akin to popular service comparators, allowing dental professionals to obtain favorable offers without hidden costs.
DyNAbind
Seed Round in 2019
Founded in 2015 and based in Dresden, Germany, DyNAbind develops regenerable biosensor drug discovery technologies. It offers DNA-encoded chemical library synthesis, selection, and decoding services, providing insights into target drugability and SAR analysis.
miRdetect
Seed Round in 2019
miRdetect GmbH is a German biotechnology company based in Bremen, established in 2016. The company develops and markets in-vitro diagnostic tests, focusing on the early detection and diagnosis of cancer. Among its products is the miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect employs advanced molecular biological techniques that enable the precise identification of minute quantities of nucleic acids, facilitating accurate cancer diagnosis. In addition to its current offerings, the company is actively engaged in research and development to create new diagnostic tests aimed at improving cancer detection capabilities.
Mediaire
Seed Round in 2019
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Plasmion
Seed Round in 2019
Plasmion specializes in developing ionization devices for scientific and industrial applications. Its flagship product, the SICRIT SC-20X ionization set, is used across various sectors such as quality control, food safety, medical diagnosis, and emission monitoring. The company serves customers globally through its network of sales partners.
8sense
Seed Round in 2019
8sense develops a smart back sensor and coaching system for office use that combines wearable sensors to analyze posture and movement with real-time feedback and training. Through games and challenges, it motivates users to care for their backs, and the accompanying coaching platform provides science-based recommendations to promote an active, dynamic sitting posture for better back health.
GWA Hygiene
Venture Round in 2018
GWA Hygiene GmbH is a German company based in Stralsund, established in 2015, that specializes in the development of hygiene monitoring solutions for healthcare settings. The company manufactures sensors designed to monitor hand hygiene standards among hospital personnel and is expanding its offerings to include surface disinfection monitoring. GWA Hygiene's technology integrates with disinfectant and soap dispensers, equipping them with sensors to capture data on disinfection practices. This data can be displayed on monitors and is accessible via a software application that analyzes disinfection rates across different wards and professional groups. Users have the option to store data on their own servers or utilize GWA Hygiene's secure cloud storage. Additionally, the company's software toolbox aids in logistical tasks related to hygiene management, such as managing dispenser refills and device maintenance.
advanceCOR
Venture Round in 2018
advanceCOR is a clinical drug development company focused on therapeutics and diagnostics for heart and vascular diseases. Its activities span research, development, and plans for commercialization to enable personalized treatment of cardiovascular conditions. Lead candidates include Revacept, a human Fc fusion protein that prevents local platelet activation at sites of vascular injury; COR-2, a recombinant protein that interferes with foam cell formation and the uptake of cholesterol; and COR-3, a recombinant protein that binds to atherosclerotic plaques and bi-specifically captures circulating progenitor cells to promote plaque healing. The company also develops antibodies and fusion proteins targeting platelet receptors and other components involved in arterial thrombosis and plaque progression, with an emphasis on addressing acute events such as myocardial infarction and stroke.
Newsenselab (M-sense)
Venture Round in 2018
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
neotiv
Seed Round in 2018
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.
heartbeat medical
Venture Round in 2017
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Signatope
Seed Round in 2017
Signatope develops protein biomarker assays leveraging mass spectrometry-based immunoassays to detect and quantify protein biomarkers across species. Founded in 2016 and based in Reutlingen, Germany, the company uses antibodies comprising epitopes of four amino acids as key reagents. Its assays support preclinical and clinical drug development by establishing quantitative measurements for the same protein across different species and isoforms, enabling clients in the pharmaceutical and chemical industries to obtain biotechnological analytics services.
KSK Diagnostics
Series A in 2017
KSK Diagnostics GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays. The company focuses on creating tests for the molecular diagnosis of infectious diseases and cancer, utilizing innovative isothermal amplification technology. These assays are designed to provide rapid results, allowing healthcare professionals to make timely diagnoses and coordinate treatment plans effectively, often within 30 minutes. In addition to its core diagnostic products, KSK Diagnostics offers customizable services for nucleic acid-based test development, including real-time PCR and RT-PCR, as well as verification, validation studies, and product enhancement services for other organizations. As a pioneering entity in its field, KSK Diagnostics is committed to advancing patient-oriented diagnostics.
Newsenselab (M-sense)
Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Evalu
Seed Round in 2016
evalu.run: The first running app that can tell you - based on your biomechanics - how fast you should run to maximize the training effect.
evalu is a Software / mobile apps company that utilizes biomedical/biomechanical user data from a textile force sensor to offer personalized sports- and rehabilitation products.
To gather the necessary data, the company offers the world's first mobile running coach (app) that can tell athletes which intensity (speed, distance, etc) is best for their training, based on their performance and a constant gait analysis during their run.
This massively increases training efficiency and limits the risk of injury.
SeNostic Health GmbH
Seed Round in 2016
SeNostic is a diagnostics company focused on developing innovative in vitro diagnostic tests for neurodegenerative disorders. The company aims to provide precise and accurate early differential diagnoses for various neurodegenerative conditions, enhancing the ability to identify specific diseases. SeNostic also specializes in offering biochemicals for neuroscience research and has created a novel method to amplify and characterize disease-specific protein aggregates found in tissues and body fluids. This approach enables better patient outcomes by facilitating timely and appropriate treatment for those affected by neurodegenerative diseases.
Abviris Deutschland
Seed Round in 2016
Abviris Deutschland GmbH is a German company founded in 2014, specializing in the development, manufacture, and marketing of in-vitro diagnostics and medical devices aimed at addressing oral cancer. Based in Ammersbek, the company focuses on utilizing immunologically active components, including a variety of antibodies targeting different types of human papilloma virus (HPV) and relevant antigens. One of its key products is PrevO-Check, an in-vitro diagnostic medical device designed for the screening of HPV-induced oral cavity cancer. Abviris Deutschland addresses the challenge of early detection, particularly since HPV infections often do not exhibit early symptoms, leading to late-stage diagnoses. The company's innovations aim to improve screening processes, especially in areas of the oral cavity that are not typically examined during standard dental visits.
heartbeat medical
Venture Round in 2016
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Venneos
Seed Round in 2015
Venneos GmbH is a high-tech startup based in Stuttgart, Germany, founded in 2014 as a spin-off from the Max Planck Society. The company specializes in developing a silicon chip-based imaging system known as 'CAN-Q' for the label-free analysis of biological cells. This innovative technology, based on CAN-Spectroscopy, allows researchers to detect cellular changes that are typically invisible to other imaging technologies. Venneos' products cater to various fields, including tumor biology, immunology, and pharmacology, providing valuable insights to researchers in academia as well as professionals in the pharmaceutical and biotech industries.
Sonormed GmbH
Series A in 2015
Sonormed GmbH is a medical technology company based in Hamburg, Germany, established in 2012. It specializes in digital audiology, developing Tinnitracks, a web application designed for tinnitus therapy. This innovative platform allows users to filter and select music that aligns with neuroscientific principles for effective treatment of tinnitus. Additionally, Tinnitracks automatically assesses music files to evaluate their therapeutic potential, providing users with feedback on the suitability of specific tracks for their therapy.
Immunservice
Series C in 2015
Immunservice is a biotechnology company focused on research and development of biomimetic immune hormone therapies, particularly interleukin-2, for cancer, viral diseases, and related conditions. It translates natural immune hormone systems into therapeutic innovations, developing biomimetic interleukin drugs that aim to enhance immune response, treat orphan indications, and support clinical development. The company works on medicinal forms of interleukin-2 that target lung metastases and tumors, including Pulmoleukin, a natural biomimetic interleukin-2 drug designed to prevent suffocation in patients with lung tumors, and also explores applications in papillomavirus-related conditions and immune rejuvenation, as well as diagnostic and treatment insights across human and animal immunotherapy and human cell therapy. It engages in patent-related activities, biomimetic therapies, and clinical development to advance these therapies.
oncgnostics
Series A in 2015
oncgnostics GmbH is a German company specializing in molecular diagnostics, particularly focused on developing in vitro diagnostic (IVD) tests for cancer. Founded in 2012 and based in Jena, oncgnostics utilizes proprietary epigenetic biomarkers to create reliable assays that facilitate early detection and diagnosis of cervical cancer and its precursors. The company's flagship product, GynTect, offers a swift and accurate method for identifying cervical cancer and pre-cancerous conditions. By targeting specific DNA regions that are methylated in precancerous and cancerous cells, oncgnostics employs established PCR-based technologies suitable for routine use in molecular diagnostics laboratories. This innovative approach not only aids in screening but also supports therapeutic decision-making and follow-up care, aiming to improve patient outcomes through early intervention.
Preventicus
Seed Round in 2014
Founded in 2014 and headquartered in Jena, Germany, Preventicus develops certified medical device software for smartphones and smartwatches. Its primary product, Preventicus Heartbeats, identifies atrial fibrillation for stroke prevention by analyzing patients' vital parameters, enabling early detection of lifestyle-related illnesses.
Predemtec
Seed Round in 2014
Predemtec GmbH is a German company established in 2011, specializing in the development and manufacture of diagnostic tests aimed at identifying risk factors for dementia and related illnesses. Based in Hennigsdorf, the company offers the Predemtec DX, a serum-based immunoassay designed for the early detection and risk assessment of senile dementia, particularly in Alzheimer's patients and those with mild cognitive impairment. This blood-based diagnostic procedure generates risk profiles by analyzing the concentration of six biomarkers using a specific algorithm, enabling healthcare providers to potentially delay the onset of dementia and mitigate its severity.
EGYM
Series B in 2014
EGYM is a global fitness technology company that empowers gym operators to deliver intelligent workout solutions through its connected gym equipment and software. It aims to enhance members' fitness journeys by providing data-based guidance, fostering physical and mental wellness.
microDimensions
Seed Round in 2014
microDimensions develops software solutions for processing, analyzing, and visualizing microscopic image data, primarily in biomedical fields. Its key products include Voloom (for automated 3D reconstruction), Zoom (for fast visualization of whole slide images), and anyslide/slidematch. These tools assist pharmaceutical, biotechnology, and pathology researchers with tasks like cell counting, tumor border computation, scoring, volume measurements, and finding regions in serial sections. microDimensions offers its products through distribution partners.
Photonics Healthcare
Venture Round in 2013
Photonics Healthcare GmbH is a medical device company based in Garching, Germany, specializing in the development and commercialization of clinical monitors for cellular oxygen measurement. The company's flagship product, the COMET Monitor, enables healthcare professionals to assess cellular oxygen metabolism, including the availability and consumption of oxygen in tissue cells. This non-invasive device provides critical data at the bedside, allowing doctors to detect hypoxia early, evaluate tissue vitality, and make informed decisions regarding treatment interventions. By accurately measuring mitochondrial oxygen availability and tension, Photonics Healthcare aims to enhance patient care and prevent potential organ failure, thereby improving the overall effectiveness of medical interventions. Additionally, the company offers contract research programs to support further advancements in the field.
Dolosys
Venture Round in 2013
Dolosys GmbH is a Berlin-based medical technology company specializing in the development and production of devices for the objective measurement of pain and pain management. The company focuses on creating innovative equipment that assists healthcare providers in monitoring and controlling pain, particularly for sedated intensive care patients and individuals suffering from chronic pain. By optimizing pain therapy, Dolosys aims to enhance pain management alternatives available to healthcare organizations, ultimately improving patient care and outcomes.
CardioSecur
Series A in 2013
CardioSecur, a subsidiary of Personal MedSystems, specializes in innovative mobile health solutions, particularly in the realm of instant cardiac monitoring. The company develops a smartphone-based ECG application that is designed to provide personalized cardiac monitoring services. This application is accompanied by a set of electrodes, allowing users to conduct high-level 12-lead ECG tests with ease. One of the key features of the application is its ability to share data with healthcare professionals, enabling patients to receive timely recommendations based on their cardiac health within minutes. CardioSecur's focus on user-friendly design and sophisticated technology positions it as a leader in the field of personalized ECG systems for individual use.
Drug Response Dx
Series A in 2013
Drug Response Dx is a biotechnology company located in Hennigsdorf, Germany, founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis (RA). Its tests focus on a protein that predicts the effectiveness of TNF-alpha inhibitors for individual patients prior to initiating medication. This approach facilitates timely treatment decisions and enhances the likelihood of successful therapeutic outcomes for patients suffering from RA. The company has established proof of concept using serum samples from RA patients, and its biomarker set is prevalidated, ensuring the reliability of its testing processes.
AYOXXA
Series A in 2012
AYOXXA Biosystems GmbH is a life science tools company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in developing a proprietary technology platform for multiplexed protein analysis. This platform, which utilizes In-situ Encoded Bead-based Arrays, enables users to simultaneously measure multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's innovative biochips merge biological analysis with information technology, expanding the potential applications in biomedical research. The company also offers biomarker kits to facilitate the identification and quantification of proteins and other biomolecular analytes.
Epivios
Venture Round in 2012
Epivios GmbH is a molecular diagnostics company based in Düsseldorf, Germany, specializing in the early detection of bladder and prostate cancer. Founded in 2011 as a spin-off from Heinrich Heine University, Epivios employs an interdisciplinary team of doctors and biologists who have been developing innovative epigenetic procedures for cancer diagnosis since 2009. The company's proprietary epigenetic platform technology incorporates a unique standardization tool that facilitates the comparison of samples with varying genetic backgrounds. This advancement allows for a comprehensive analysis of genetic sequences across the entire genome, enhancing the accuracy and effectiveness of cancer diagnostics.
oncgnostics
Seed Round in 2012
oncgnostics GmbH is a German company specializing in molecular diagnostics, particularly focused on developing in vitro diagnostic (IVD) tests for cancer. Founded in 2012 and based in Jena, oncgnostics utilizes proprietary epigenetic biomarkers to create reliable assays that facilitate early detection and diagnosis of cervical cancer and its precursors. The company's flagship product, GynTect, offers a swift and accurate method for identifying cervical cancer and pre-cancerous conditions. By targeting specific DNA regions that are methylated in precancerous and cancerous cells, oncgnostics employs established PCR-based technologies suitable for routine use in molecular diagnostics laboratories. This innovative approach not only aids in screening but also supports therapeutic decision-making and follow-up care, aiming to improve patient outcomes through early intervention.
Eyesight & Vision GmbH
Seed Round in 2011
Eyesight & Vision GmbH, founded in 2010 and based in Nürnberg, Germany, specializes in the development and marketing of advanced diagnostic equipment for refractive error measurement during cataract surgery. The company's flagship product, the Intraoperative Ocular Wavefront Aberrometer (I-O-W-A), enhances surgical precision by providing surgeons with real-time data on the refractive power of the eye and the positioning of intraocular lenses (IOLs). This innovative system employs patented "flying spot" technology, facilitating rapid and reliable measurements that integrate seamlessly with existing surgical microscopes. Eyesight & Vision GmbH focuses on optimizing the selection and placement of IOLs, ultimately aiming to improve patient outcomes and satisfaction in refractive cataract and lens surgeries.
Humedics
Series A in 2011
Humedics develops a breath analysis device that measures liver function in real-time. Its LiMAx test enables clinicians to quantitatively determine individual liver function capacity, supporting treatment decisions and improving patient outcomes. The company focuses on applications such as liver transplantation diagnosis, living donor assessment, and disease evaluation.
Capical
Seed Round in 2011
Capical GmbH is a German company specializing in the development and marketing of innovative electrocardiography (ECG) devices that utilize capacitive electrode technology for contact-free patient monitoring. Founded in 2010 and based in Braunschweig, Capical has established itself as a leader in this field, focusing on high-resolution ECG measurements that allow healthcare professionals to assess heart activity without direct skin contact. The company’s technology finds applications beyond healthcare, including in automotive and furniture sectors, where it can monitor driver states and physiological parameters in various settings. Capical is committed to research and development, continuously enhancing its product offerings, and has received multiple awards for its achievements in technology transfer and innovation. The company aims to enhance the quality of life for individuals, especially the elderly or those with health challenges, while also improving safety and comfort in automated driving environments.
Lophius Biosciences
Venture Round in 2011
Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the diagnosis and management of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, elispot kits, antibodies, and related materials. Lophius Biosciences employs proprietary technologies such as T-activation® and Reverse T Cell Technology, which enable efficient stimulation of immune effector cells and allow differentiation between active and memory T cells. This expertise facilitates accurate measurement of cell-mediated immunity, supporting personalized treatment strategies for patients, particularly in transplantation and infectious disease contexts. Additionally, the company provides custom services in cell-based bioactivity and quality testing for pharmaceutical agents.
EGYM
Pre Seed Round in 2011
EGYM is a global fitness technology company that empowers gym operators to deliver intelligent workout solutions through its connected gym equipment and software. It aims to enhance members' fitness journeys by providing data-based guidance, fostering physical and mental wellness.
Gilupi
Series C in 2011
GILUPI GmbH is a medical device company based in Potsdam, Germany, specializing in the development and production of diagnostic products aimed at the in vivo isolation of rare cells from circulating blood. The company's primary focus is on isolating tumor cells, utilizing devices that employ predetermined selectivity of antibodies bound to nano-detectors. This technology enables healthcare professionals to effectively isolate circulating tumor cells within patients' blood, facilitating more precise diagnoses and tailored therapeutic interventions. GILUPI's devices are CE certified, ensuring their compliance with safety and efficacy standards, which enhances their credibility and utility in clinical settings.
Curefab Technologies
Venture Round in 2010
Curefab Technologies is a developer of advanced medical technologies focused on the objective quantitative assessment of diagnostic image data. The company's innovations enhance diagnostic certainty, facilitating early detection of cardiovascular and oncological diseases. Curefab's technologies play a crucial role in stroke prevention, the early diagnosis of vascular conditions, and the monitoring of cancer therapies. Additionally, the company offers computed sonography systems that allow for the comparison and analysis of ultrasound images, thereby providing physicians with relevant diagnostic parameters essential for patient care.
Biametrics
Seed Round in 2010
Biametrics is a company that specializes in providing advanced research and development services tailored for the academia, pharmaceutical, biotechnology, and diagnostic sectors. Its products focus on label-free detection systems that characterize biomolecular interactions by delivering critical kinetic and affinity data, as well as thermodynamic information such as enthalpy and entropy. By employing innovative technological methods, Biametrics enhances the capabilities of its clients in data evaluation, facilitating applications that range from diagnostics to process analytics. The company's solutions are designed to offer unmatched performance in throughput and versatility, meeting the diverse needs of scientists in their research endeavors.
ChromoTek
Venture Round in 2010
ChromoTek GmbH is a biotechnology company based in Planegg-Martinsried, Germany, founded in 2008. The company specializes in the development of innovative immunologic research tools and detection reagents aimed at enhancing proteomics and cell biology applications. ChromoTek's products are derived from single domain camel antibodies, providing advanced solutions for health institutions and researchers. By offering these unique tools, ChromoTek aims to improve research capabilities and outcomes in various scientific fields worldwide.
Zedira
Seed Round in 2010
Zedira GmbH is a biopharmaceutical company based in Darmstadt, Germany, founded in 2007. It specializes in the development of drugs and diagnostic tools related to celiac disease, focusing on transglutaminase. The company is recognized for its TG6 marker, which aids in the detection of neurological disorders linked to gluten. Zedira also produces a range of specialty reagents to support researchers in studying celiac disease, including active ingredients, diagnostic antigens, proteases, assays, substrates, antibodies, inhibitors, and autoantibody detection ELISA kits. With a commitment to advancing understanding and treatment of celiac disease, Zedira engages in drug discovery programs aimed at developing small molecular drug candidates that inhibit dysregulated transglutaminases, thereby enhancing therapeutic options for patients.
Lophius Biosciences
Series B in 2010
Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the diagnosis and management of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, elispot kits, antibodies, and related materials. Lophius Biosciences employs proprietary technologies such as T-activation® and Reverse T Cell Technology, which enable efficient stimulation of immune effector cells and allow differentiation between active and memory T cells. This expertise facilitates accurate measurement of cell-mediated immunity, supporting personalized treatment strategies for patients, particularly in transplantation and infectious disease contexts. Additionally, the company provides custom services in cell-based bioactivity and quality testing for pharmaceutical agents.
Delphi Optics GmbH
Seed Round in 2010
Delphi Optics GmbH is a Germany-based company that develops and distributes automatic, optical classification systems for medical applications. It was founded in 2009 and is headquartered in Lübeck, Schleswig-Holstein.
Humedics
Seed Round in 2010
Humedics develops a breath analysis device that measures liver function in real-time. Its LiMAx test enables clinicians to quantitatively determine individual liver function capacity, supporting treatment decisions and improving patient outcomes. The company focuses on applications such as liver transplantation diagnosis, living donor assessment, and disease evaluation.
SurgicEye
Series A in 2010
SurgicEye GmbH, founded in 2008 and based in Munich, Germany, develops advanced intra-operative imaging and instrument navigation solutions for surgical procedures. The company specializes in navigated radio-guided surgery through its declipse SPECT open surgery technology, which utilizes handheld 3-D freehand SPECT imaging. It also offers the declipse SPECT Laparascopy, an intraoperative 3D imaging system designed for invasive sentinel lymph node biopsy, and the declipse SPECT imaging probe, a compact mobile SPECT imaging solution with high resolution. In addition to its imaging technologies, SurgicEye provides consulting services for medical device development, including requirements engineering, software specification, software development and testing, as well as support for the design and conduction of clinical studies.
PluriSelect
Venture Round in 2009
PluriSelect is a developer of biotechnical devices and supplies that focus on providing efficient tools for cell and protein separation. The company's products facilitate the isolation of cells from various sources, including whole blood, buffy coat, and cell culture, as well as other heterogeneous biological liquids. By enabling researchers to isolate specific targets from unbound materials, PluriSelect's solutions help academic scientists achieve high-quality results while minimizing the time and resources required for routine tasks.
SurgicEye
Seed Round in 2008
SurgicEye GmbH, founded in 2008 and based in Munich, Germany, develops advanced intra-operative imaging and instrument navigation solutions for surgical procedures. The company specializes in navigated radio-guided surgery through its declipse SPECT open surgery technology, which utilizes handheld 3-D freehand SPECT imaging. It also offers the declipse SPECT Laparascopy, an intraoperative 3D imaging system designed for invasive sentinel lymph node biopsy, and the declipse SPECT imaging probe, a compact mobile SPECT imaging solution with high resolution. In addition to its imaging technologies, SurgicEye provides consulting services for medical device development, including requirements engineering, software specification, software development and testing, as well as support for the design and conduction of clinical studies.
Public Health Solutions
Venture Round in 2008
Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.
Lophius Biosciences
Seed Round in 2008
Lophius Biosciences GmbH is a biotechnology company based in Regensburg, Germany, specializing in the development of innovative immune diagnostic systems aimed at enhancing the diagnosis and management of acute infectious and autoimmune diseases. Founded in 2002, the company focuses on immunology and T-cell diagnostics, offering a range of products including diagnostic kits, elispot kits, antibodies, and related materials. Lophius Biosciences employs proprietary technologies such as T-activation® and Reverse T Cell Technology, which enable efficient stimulation of immune effector cells and allow differentiation between active and memory T cells. This expertise facilitates accurate measurement of cell-mediated immunity, supporting personalized treatment strategies for patients, particularly in transplantation and infectious disease contexts. Additionally, the company provides custom services in cell-based bioactivity and quality testing for pharmaceutical agents.
Corimmun
Series A in 2008
Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany, specializing in innovative therapeutics and diagnostics for heart and vascular diseases. The company is dedicated to addressing unmet medical needs in the field of cardiovascular health. Corimmun's expertise encompasses the entire process of drug development, from initial research through to commercialization. By focusing on novel treatment options, Corimmun aims to improve outcomes for patients suffering from cardiovascular conditions.
Sense Inside
Venture Round in 2008
Sense Inside is a company that specializes in the development of a unique diagnostic and therapeutic device aimed at addressing bruxism, a condition characterized by pathological teeth grinding. The device is designed to provide long-term solutions for both diagnosis and treatment, catering to a growing patient population experiencing significant physiological strain associated with dental issues. By enabling healthcare professionals to effectively diagnose and manage bruxism, Sense Inside plays a crucial role in the broader context of dental health and patient care.
awenydd diagnostics GmbH
Venture Round in 2008
awenydd diagnostics GmbH is a Germany-based company that analyzes patients and interactions they have with other drugs.
Immunservice
Seed Round in 2008
Immunservice is a biotechnology company focused on research and development of biomimetic immune hormone therapies, particularly interleukin-2, for cancer, viral diseases, and related conditions. It translates natural immune hormone systems into therapeutic innovations, developing biomimetic interleukin drugs that aim to enhance immune response, treat orphan indications, and support clinical development. The company works on medicinal forms of interleukin-2 that target lung metastases and tumors, including Pulmoleukin, a natural biomimetic interleukin-2 drug designed to prevent suffocation in patients with lung tumors, and also explores applications in papillomavirus-related conditions and immune rejuvenation, as well as diagnostic and treatment insights across human and animal immunotherapy and human cell therapy. It engages in patent-related activities, biomimetic therapies, and clinical development to advance these therapies.
Corimmun
Seed Round in 2007
Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany, specializing in innovative therapeutics and diagnostics for heart and vascular diseases. The company is dedicated to addressing unmet medical needs in the field of cardiovascular health. Corimmun's expertise encompasses the entire process of drug development, from initial research through to commercialization. By focusing on novel treatment options, Corimmun aims to improve outcomes for patients suffering from cardiovascular conditions.
Public Health Solutions
Series A in 2006
Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.
Scylab medic
Series A in 2006
Scylab medic develops an environment sensing device for blind and visually impaired people. Its products include feelix, a light device that uses a 3D sensor to facilitate the user to partially recognize surroundings without physically touching, as well as to identify stationary and moving objects. The company was founded in 2006 and is based in Leipzig, Germany.
multiBIND biotec
Venture Round in 2006
multiBIND biotec GmbH, founded in 2005 and based in Dortmund, Germany, specializes in the development of innovative solutions for decontamination and disinfection. The company's flagship technology, bioDECONT®, effectively addresses issues related to horizontal gene transfer by facilitating the removal of genetic material, proteins, and lipids. Additionally, multiBIND biotec offers bioCLEAN, which provides antimicrobial and antiviral solutions, and CleanExtract, a rapid assessment tool for microbial ATP levels in various challenging substances, including lubricants and emulsions. Through its focus on molecular genetics and biomedicine, multiBIND biotec aims to enhance safety and efficacy in environments requiring stringent contamination control.
awenydd diagnostics GmbH
Seed Round in 2006
awenydd diagnostics GmbH is a Germany-based company that analyzes patients and interactions they have with other drugs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.